Understanding the molecular components of odors used by trained dogs to detect prostate cancer could help researchers to develop computers with ... Read more
Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can accurately identify which men with intermediate- or high-risk ... Read more
Combining Erleada (apalutamide) and Zytiga (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC) significantly extends the time patients live without signs ... Read more
When given in combination with androgen deprivation therapy or ADT, Erleada (apalutamide) significantly prolonged the lives of men with metastatic hormone-sensitive ... Read more
Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of ... Read more
Dosing has begun in a Phase 1 clinical trial testing Forma Therapeutics’ investigational therapy FT-7051 in people with metastatic castration-resistant prostate cancer ... Read more
CRY-1, a regulator of our circadian clocks, contributes to disease spread and poor outcomes in prostate cancer patients by boosting DNA repair ... Read more
Essa Pharma has entered a clinical collaboration with Janssen to evaluate its small molecule inhibitor EPI-7386, in combination with either Erleada (apalutamide) ... Read more
